SCN’s mandate is to act as a catalyst for enabling the translation of stem cell research into clinical applications, commercial products and public policy.
In just over 15 years SCN has forged a national community that has transformed stem cell research in Canada, brought research to the point where regenerative medicine is changing clinical practice and established an outstanding international reputation. SCN has pushed the boundaries of what was a basic research area towards translational outcomes for the clinic and marketplace.
By the end of 2016, SCN will have provided over $90 million for innovative translational research. This strategic funding has benefitted approximately 150 world-class research groups and more than 2,500 trainees from across Canada. Additionally, SCN has catalyzed 12 clinical trials and 11 start-up companies. SCN investigators have leveraged upwards of $80 million in partner contributions while SCN has incubated several international and Canadian research networks and organizations.